Interim impact evaluation of the hepatitis C virus elimination program in Georgia

JosephineWalker*1,AaronLim1,HannahFraser1,LiaGvinjilia6,LieslHagan2,TinatinKuchuloria6,NatashaKMartin9,MuazzamNasrullah2,ShaunShadaker2,MalvinaAladashvili11,AlexanderAsatiani5,DavitBaliashvili5,MaiaButsashvili12,IvdityChikovani4,IrmaKhonelidze5,IrmaKirtadze3,MarkKuniholm10,DavidOtiashvili3,KetevanStvilia5,TengizTsertsvadze11,MattHickman1,JulietteMorgan7,AmiranGamkrelidze5,ValeriKvaratskhelia8,FranciscoAverhoff2,PeterVickerman1

*Correspondenceto:J.G.Walker@bristol.ac.uk

1. PopulationHealthSciences,BristolMedicalSchool,UniversityofBristol

2. DivisionofViralHepatitis,NationalCenterforHIV/AIDS,ViralHepatitis,STDandTBPrevention,CDC

3. AddictionResearchCenterAlternativeGeorgia

4. CuratioInternationalFoundation

5. NationalCenterforDiseaseControlandPublicHealthofGeorgia,Tbilisi,Georgia

6. CDCFoundation,Tbilisi,Georgia

7. GlobalDiseaseDetection,DivisionofGlobalHealthProtection,SouthCaucasusCDCOffice,Tbilisi,Georgia

8. MinistryofLaborHealthandSocialAffairsofGeorgia,Tbilisi,Georgia

9. DivisionofGlobalPublicHealth,UCSanDiego,California,USA

10. DepartmentofEpidemiologyandBiostatistics,UniversityatAlbany,StateUniversityofNewYork

11. InfectiousDiseases,AIDSandClinicalImmunologyResearchCenter,Tbilisi,Georgia

12. Neolab,Tbilisi,Georgia

NOTE:THISISADRAFTTHATISUNDERGOINGCDCCLEARANCEANDWILLBEUPDATEDWHENAPPROVED

peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/270579doi: bioRxiv preprint first posted online Feb. 24, 2018;

Abstract BackgroundandAims:GeorgiahasoneofthehighesthepatitisCvirus(HCV)prevalenceratesintheworld,with>5%oftheadultpopulation(~150,000people)chronicallyinfected.InApril2015,theGeorgiangovernment,incollaborationwithCDCandotherpartners,launchedanationalprogramtoeliminateHCVthroughscalingupHCVtreatmentandpreventioninterventions,withtheaimofachievinga90%reductioninprevalenceby2020.WeevaluatetheinterimimpactoftheHCVtreatmentprogramasof31October2017,andassessthefeasibilityofachievingtheeliminationgoalby2020.

Method:WedevelopedadynamicHCVtransmissionmodeltocapturethecurrentandhistoricalepidemicdynamicsofHCVinGeorgia,includingthemaindriversoftransmission.Usingthe2015nationalsero-surveyandpriorsurveysconductedamongpeoplewhoinjectdrugs(PWID)from1997-2015,themodelwascalibratedtodataonHCVprevalencebyage,genderandPWIDstatus,andtheagedistributionofPWID.WeusethemodeltoprojecttheinterimimpactoftreatmentstrategiescurrentlybeingundertakenaspartoftheongoingGeorgiaHCVeliminationprogram,whileaccountingfortreatmentfailure/losstofollowup,inordertodeterminewhethertheyareontracktoachievingtheirHCVeliminationtargetby2020,orwhetherstrategiesneedtobemodifiedtoensuresuccess.

Results:Atreatmentrateof2,050patients/monthwasrequiredfromthebeginningofthenationalprogramtoachievea90%reductioninprevalencebytheendof2020,withequaltreatmentratesofPWIDandthegeneralpopulation.FromMay2015toOctober2017,40,420patientsweretreated,anaverageof~1,350permonth;althoughthetreatmentratehasrecentlydeclinedfromapeakof4,500/monthinSeptember2016to2100/monthinNovember-December2016,and1000/monthinAugust-October2017,withasustainedvirologicalresponserate(SVR)of98%per-protocolor78%intenttotreat.ThemodelprojectsthatthetreatmentsundertakenuptoOctober2017havereducedadultchronicprevalenceby26%(18-35%)to3.7%(2.9-5.1%),reducedtotalincidenceby25%(15-35%),andprevented1845(751-3969)newinfectionsand93(31-177)HCV-relateddeaths.Ifthetreatmentrateof1000patientsinitiatedpermonthcontinues,prevalencewillhavehalvedby2020,andreduceby90%by2026.Inordertoreacha90%reductionby2020,thetreatmentratemustincrease3.5-foldto4000/month.

Conclusion:TheGeorgiaHCVeliminationprogramhasaccomplishedanimpressivescaleupoftreatment,whichhasalreadyimpactedonprevalenceandincidence,andaverteddeathsduetoHCV.However,extensivescaleupisneededtoachievea90%reductioninprevalenceby2020.

Introduction HepatitisCvirus(HCV)causeslong-termliverdamageandprogressiontoendstageliverdisease1,2,withdeathsduetoHCVbeinggreaterthanmalariain2015(~400,000)3.Anestimated71millionpeopleareinfectedworld-wide,with80%concentratedinlowandmiddleincomecountries(LMIC)4.HCVisahighlytransmissibleblood-borneinfectionprimarilytransmittedbyinjectingdruguseandunsafemedicalprocedures.Untilrecently,theonlytreatmentsavailableforHCVhadpoorefficacy,longduration(24-48weeks)andwerepoorlytolerated.However,newhighlyeffectiveall-oraldirect-actingantiviral(DAA)treatmentsarenowavailable,whichhavemadeHCVaneasilycurableinfection.

TheWorldHealthOrganization(WHO)adoptedthefirstglobalhealthsectorstrategyonviralhepatitis(SVH)in2016,whichrecognizedviralhepatitisasaninternationalpublichealthpriorityandproposedeliminatingitasamajorpublichealththreatby20303.Priortothis,therepublicofGeorgia,whichhasoneofthehighestprevalencesofHCVglobally(5.4%chronicinfectionprevalenceamongadultsin20155),launchedthefirstnationalHCVeliminationprogram6,aimingtoreduceHCVprevalenceby90%by2020.

Georgiahasapopulationof3.7millionpeople,withanestimated150thousandchronicinfectionsofHCVamongadults.RecentadvancesintreatmentforHCV,alongwiththecountry’ssmallpopulation,andpoliticalandpublicsupportledtothedevelopmentofaHCVeliminationprogrammeforGeorgia,supportedbyGilead6.Tohelpguidetheeliminationprogramme,anationalserosurveywasconductedin20157.TheserosurveyfoundheterogeneouslevelsofHCVinfectionbygenderandage.Thehighestlevelofchronicinfection(>15%)wasamongstmenaged30-49years,withmuchlowerprevalenceratesinfemales(adultprevalence2.2%).ThisheightenedHCVtransmissionamongstmenisthoughttohaveoccurredduringtheperiodofunrestaroundthecollapseoftheSovietUnionin1991,whentwocivilwarsandgeneraleconomiccollapse8resultedinhighratesofdrugtraffickingandinjectiondruguse(IDU)inGeorgia9.Sincethen,druguseisthoughttohavediminished,althoughrecentestimates(2007-2016)stillsuggestabout2%ofadultsarepeoplewhoinjectdrugs(PWID,40-52,500)10–12,whichishighcomparedtoaglobalaverageof0.33%???.Transmissionisalsothoughttohavebeendrivenbyiatrogenictransmission,withtheoverallqualityofmedicalcareandbloodtransfusionsafetyremaininglowuntilatleast200913.TheagedistributionandpresumedhistoricalpatternsoftransmissionsuggestthattheHCVepidemicisindecline,butthatacohortofadultsinfected20-30yearsagoarelikelytobeprogressingtowardsadvancedliverdiseasesoneedingurgenttreatment.

WedevelopedadynamicHCVtransmissionmodeltocapturetheevolvingepidemicofHCVinGeorgia,incorporatingthemaindriversoftransmission.WeusethemodeltoestimatetheinterimimpactoftheGeorgianHCVeliminationprogram,andthendeterminewhethertheyareontracktoachievingtheirHCVeliminationtargetsby2020orwhetherstrategiesneedtobemodifiedtoensuresuccess.

Methods

Model description and initialisation

WedevelopedamodelofHCVtransmissionincorporatingthechangingdemographicsofPWIDandthegeneralpopulationinGeorgia(Figure1).TheframeworkofthemodelusedisbasedonatraditionalSI(susceptible-infected)model,becausethemajorityofHCVexposuresleadtolife-longchronicinfection14.Curativetreatmentisincorporated(representedbyacompartmentT),whichifsuccessfulleadstoindividualsbecomingsusceptibleagain.Themodelalsoincludesgender,nineageclasses(Figure1C),anddividesallindividualsintonon-PWID,activePWID,andex-PWID.

Individualsenterthemodelintheyoungestagegroupassusceptiblenon-PWID,equallydividedbetweenmalesandfemales.Individualsthentransitionthroughtheagecategories,withaproportiontransitioningtoIDUfromallagecategoriesuptoage39,atageandgender-specificrecruitmentrates.PWIDexperiencedrug-relatedmortality,andcessatefrominjectingatage-specificratestobecomeex-PWID,whodieatthesameage-specificratesasnon-PWID.

SusceptibleindividualsbecomeinfectedataratethatisproportionaltoHCVprevalence,witharateoftransmissionthatappliestothewholepopulation,andanadditionalrateoftransmissionamongstcurrentPWID.BoththesetransmissionrisksareallowedtovaryovertimetoaccountforchangesininterventioncoverageinGeorgia.Themodelalsoallowedforthepossibilityofassortative‘like-with-like’mixingwhenyoung(<30years)andolder(>30years)PWIDformtransmissioncontacts,varyingbetweenrandommixingacrosstheseagegroupstopreferentialmixingonlybetweenPWIDofthesameagegroup.

Uponinfection,someindividualsspontaneouslycleartheirinfection,withtheremainderdevelopingchronicinfectionandgraduallyprogressingthroughdifferentstagesofliverdisease(Figure1B).Individualswithdecompensatedcirrhosis(DC)orhepatocellularcarcinoma(HCC)experienceheightenedmortality.Treatmentoccursatatime-varyingrate,withsuccessfullycuredindividualsreturningtothesusceptiblestatewiththeircorrespondinglevelofliverdisease,whilethosefailingtreatmentreturntotheinfectedstate.Aftersuccessfultreatment,liverdiseaseprogressionhaltsforindividualscuredwithmildormoderateliverdisease,whileitcontinuesataslowerrateforthosewithcompensatedcirrhosisormoreprogresseddisease.IndividualswithdecompensatedcirrhosisorHCCarenoteligiblefortreatment.

Themodelwasinitializedin1900withapopulationsizeof4million,allsusceptible,non-PWID,andwithnoliverdisease,distributedequallyacrossgenderandagecompartments.Injectingdruguseisassumedtostartin1960.TogeneratearapidincreaseininfectionamongstPWID,HCVisseededinthispopulationwitha10%annualrateofinfectionforsusceptiblePWID<30yearsoldinthefirstfiveyearsafter1960.

Model parameterization and calibration

Calibration and validation data

Themodelwascalibratedto,andcomparedagainstavailabledataontheprevalenceofHCVfromthe2015NationalSerosurveyandsevenIntegratedBiologicalandBehavioralSurveillance(IBBS)surveysofPWIDfrom1997-2015(Table3).Sero-prevalenceestimatesfromIBBSsurveyswereconvertedtochronicprevalencebasedontheratioofchronictoantibodyprevalenceintheNationalSerosurvey(72%).TheNationalSerosurveyprovidedgender-specificHCVprevalencesinthegeneralpopulation,groupedintothreeagecategories(18-29,30-49,and50+),whiletheIBBSprovidedyearspecificHCVprevalenceestimatesforallPWID,youngPWID(18-24)andolderPWID(25+).TheHCVprevalenceestimatesusedtocalibratethemodelaregiveninTable3,withspecificprevalenceratiosbeingusedtocalibratethemodeltoensureitcapturesincreasesinHCVprevalenceamongstallPWID(16%relativeincreaseover2006-2015),andthelargevariationsinHCVprevalencebyageamongstmales.DatafromtheotherIBBSsurveys(2001,2007-2012)wereusedformodelvalidation.InadditiontoHCVprevalencedata,themodelwasalsocalibratedtotheoverallpopulationsizeinGeorgiain2015(estimatedfrom2014nationalcensus15),theestimatednumberofPWIDin2014(estimatedasaconsensusofalternativesizeestimates11),andtheproportionofPWIDthatare18-29and30-49inthe1998and2015IBBS(Table3).ThislastdatawasincludedtoensurethemodelcapturesthedecreaseinrecruitmentofnewPWIDbetweenthesedates.

Tocomparewithourmodelpredictions,wealsoestimatedtheobservedincidenceinPWIDbetween1997-2001basedonpreviouslyunpublisheddatafromacohortofPWIDinGeorgia(seesupplementarymaterials).

Model Parameterisation

ThemodelwasparameterisedusingdatafromthePWIDIBBSsurveys,theNationalSerosurvey,thetreatmentdatabasefortheGeorgianeliminationprogram,publishedliteratureandWHOdatabases.Allmodelparameters,uncertaintydistributionsandtheirdatasourcesaregiveninTable1andTable2.

DiseaseprogressionandHCV-relateddeathrateswereobtainedfromtheliterature16–18.DataonHCVtreatmentrates(seenextsection)werenotusedinthemodelfittingbecauseitbeganafterthelastprevalencedatausedinthemodelfitting(mid-2015).

Gender-andage-specificmortalityrateswereobtainedfrom2015lifetablesforGeorgia19,withPWIDhavinganelevatedmortalityratiobasedonPWIDmortalitydatafromEasternEurope20.Themodeldoesnotaccountforimmigration/emigrationorchangesinpopulationsize.

ThenumberofPWIDinGeorgiaisunderstoodtohaveincreaseddramaticallyalongsidethefalloftheUSSRandresultingsocial,political,andeconomiccrises9,21.Officialrecordsofdrugusers(diagnosedasdrugdependentbypolice)increasedeighttimesbetween1990and2004,from2,700to21,000,butunfortunatelyunbiasedestimatesofthenumberofPWIDoverthistimeperiodarenotavailable21.Recentestimatesfrom2007-2014suggesta

stablePWIDpopulationinGeorgiaofabout50,00011,whileIBBSdatafrom1998-2015suggestanagingPWIDpopulation,likelyduetoreducedinitiationofinjecting(SupplementaryFigure3).ToaccountforthelikelychangingdynamicsofIDUinGeorgia,weassumedatransientpeakintheinitiationofIDU,allowingconsiderableuncertaintyinwhenthisoccurredanditsmagnitude(Table1).UncertaintyalsoexistsaroundthedurationthatPWIDinjectfor,whichwasgivenwideuncertaintyboundsandallowedtovaryacrossagegroups.ThewidepriorrangesfortheserecruitmentandcessationparameterswereconstrainedthroughfittingthemodeltoIBBSdataontheproportionofPWID18-29and30-49in1998and2015,theestimatedpopulationsizeofPWIDin2014,andtheproportionofPWIDthatarefemale(fromNationalSerosurvey).

Harmreduction(HR)interventionsintheformofneedleandsyringeprovisionprograms(NSP)waswerefirstintroducedinGeorgiain1999,andopioidsubstitutiontherapy(OST)wasintroducedin200522.Sincethen,bothinterventionshavescaledup,with4.5millionsyringekitsand30,330PWIDreachedbyNSPin2016(GeorgiaHarmReductionNetwork,unpublisheddata)and4450PWIDonOSTin201523,24.TheimpactofOSTisincludedinthemodelbyreducingtheriskofHCVacquisition(basedonarecentCochranereview25)fortheproportionofPWIDonOSTovertime23,24.However,becauseuncertaintyexistsintheimpactofNSPinGeorgia,weallowedNSPtohavegreaterimpactonpopulation-levelHCVtransmission.ThiswasdonetocapturethehalvinginHCVprevalenceamongstyoungPWID(<30years)inIBBSsurveysbetween1997and2006,whichsuggeststhatHCVincidenceinPWID,particularlyinyoung/newPWID,mayhavedeclinedoverthisperiod(SupplementaryFigure4).WealsoundertookasensitivityanalysiswheretheimpactofNSPisuseddirectlyfromtheCochranereview25.

InadditiontointerventioneffectsonHCVtransmissionamongstPWID,theriskofHCVtransmissioninthegeneralpopulationwasallowedtoreducedatapointintimetoaccountforotherpreventionmeasures,suchastheintroductionofdonorbloodscreening.

Model Calibration

WeusedamodifiedMarkovChainMonteCarloApproximateBayesianComputation(MCMC-ABC)approachtocalibratethemodel26,27inRversion3.3.228(seesupplementarymaterial).Themethodobtainsaprobabilitydistributionofparametervalues(theposterior)thatconstraintheinitialpriorrangesformodelparameters,producingmodelfitsthatincorporatetheuncertaintyinthemodelparametersandthecalibrationdata.Allparametersaresimultaneouslyindependentlysampledfromtheirprioruncertaintyranges,withtheparametersamplingdistributionsbeingadjustediterativelybasedonhowwelleachsampledrunagreeswiththecalibrationdata.Importantly,thisincludeshighlyuncertainparameters,suchastransmissionrates,whichwillbenarroweddownbasedonfittingthemodeltodata.

TheparametersetsidentifiedthroughMCMC-ABCwerefurtherfilteredtoonlyretainthosethatagreed(layin95%confidenceintervals)withtheoverallHCVprevalence(4.51-6.32%)andtotalfemaleHCVprevalence(1.55-2.86%)fromthe2015NationalSerosurvey,andtheHCVprevalenceamongstPWIDfromthe2015IBBS(45.5-56.1%)29.Thesefilteredmodelrunsweredenotedasthebaselinemodelfits.

Intervention analyses

Thebaselinemodelfitswerefirstlyusedtoestimatetheinterimimpactoftheexistingscale-upintreatmentfromMay2015toOctober2017inGeorgia.Thisutiliseddatafromthetreatmentprogramonthenumberofinfectedindividualsinitiatingtreatment,includingtreatmentstargetedtopatientswithcirrhosisbeforeJune2016(Table4).BeforeMarch2016,sofosbuvirwithribavirinwasused,achievingper-protocolSVR(sustainedviralresponse)of80.4%,whileafterthis,ledipasvirwithsofosbuvir(Harvoni,Gilead)wasused,resultinginanSVRof98.5%(GeorgiaMinistryofLabor,Health,andSocialAffairs[MoLHSA],unpublisheddata).WecalculatedITTSVRratesforpre-cirrhoticandcirrhoticpatients,andanintermediatecureratetakingintoaccountpatientswhowereknowntohavecompletedtreatmentbutdidnotreturnforSVRtesting12weeksafterfinishingtreatment(seesupplementarymaterialsandTable4).

Duetodatalimitations,therewasuncertaintyoverthenumberofPWIDthatweretreated.Inthebasecase,weassumedPWIDweretreatedatthesamerateastherestofthepopulation,andcomparedtheseresultstoscenarioswherePWIDreceivednegligibletreatment,orweretreatedatdoubletherateoftherestofthepopulation.

ImpactwasestimatedintermsoftherelativedecreaseinincidenceandprevalencefromMay2015toOctober2017,aswellasthenumberofdeathsandinfectionsavertedoverthisperiod,comparedtoifnotreatmenthadoccurred.Thenumberofinfectionsanddeathsavertedwerealsoestimateduptotheendof2030,assumingtreatmentstoppedafterOctober2017.

Followingthis,weevaluatedtheimpactofalternativeinterventionstrategiesgoingforward(fromNovember2017),toassesswhatisrequiredtoensuretheeliminationprogramreduceschronicprevalenceby90%by2020,comparedtoprevalencelevelsinMay2015.Weconsidereddifferenttreatmenttargetingscenarios,withtreatmentseitherdistributedequallyacrossriskgroupsanddiseasestagesoralternativelytargetedtoPWID(attwicetherateofothergroups)ornot(PWIDnotbeingtreated),ortocirrhotics(80%ofinfectedindividualswithcirrhosis(F4)treatedannually).Foreachscenario,weconsideredtheimpactupto2020ofeithermaintainingthecurrenttreatmentrateachievedbetweenAugust-October2017(1000permonth),orscalinguptoachievetheGeorgiangovernment’sestimateofthenumberoftreatmentsnecessary(128,250)todiagnose90%ofcasesandtreat95%oftheseinfections(90-95target).Foreachtreatmenttargetingscenario,welastlyestimatedthetreatmentraterequiredfromNovember2017toachievetheGeorgianeliminationtargetofreducingprevalenceby90%byDecember2020(comparedtoJanuary2015levels).Wealsoestimatedwhatthiswouldachieveintermsofdecreasingincidence,andnumberofinfectionsanddeathsavertedby2020.

Sensitivity analysis

Weundertookasensitivityanalysistodeterminehowtherequiredtreatmentrateforachievinga90%decreaseinprevalenceby2020wouldchangeif:harmreductioninterventionswerealsoscaledupoverthisperiodto75%coverageforOSTandNSP;thetreatmentprogramachievedthehigherperprotocolSVRratesamongstallpatients;orif

existingharmreductioninterventionshadalowerimpactasestimatedbyaCochranereview25(seemodelparameterizationsection).

Results

Baseline epidemic projections without treatment

Aftermodelcalibration,554parametersetswereretainedwhichfittheobservedPWIDdemographicsandHCVprevalenceforGeorgia(Figure2,Figure3,SupplementaryFigure2).PriorandposteriorparameterdistributionsarepresentedinSupplementaryFigure1.

ThebaselinemodelfitssuggestthatHCVprevalenceinPWIDisdecliningovertime(Figure5,middlepanel)andHCVincidenceinPWID(Figure6,middlepanel)isdecreasingorstayingstable(percentdecrease10%(-110-99%from2010to2015).ThepopulationofactivePWIDisalsodecliningfromapeakof128815(50583-325756)in2002,withacurrentpopulationsizeof64420(17598-152152).ThemodelisconsistentwithrecentestimatesoftheadultPWIDpopulation,butthemodelledestimatesforthepopulationofformerPWIDismorethandoubletheestimatefromthe2015nationalsurvey,inwhich4.2%(3.5-5.2%)ofadultsreportahistoryofinjectingdruguse,indicatingapopulationof116,760formerPWID(Figure4).However,thisriskfactorislikelytobeunderreported.

ThealternativemodelcalibrationestimatesamuchgreaterdeclineinHCVincidenceamongstPWID,whilethepopulationsizeofPWIDshowslessfluctuationthaninthemaincalibrationscenario(seesupplementarymaterialforresultsusingthismodelcalibration).

WiththesizeofthePWIDpopulationandHCVdecreasing,themodelalsoprojectsthattheHCVpopulationattributablefractionforinjectingdruguse(PAF)hasdecreaseddramatically,withPWIDbeingthemaindriversoftheHCVepidemicinthepast,butnotnow.TheHCVproportionattributablefraction(PAF)hasdeclinedfrom71%(38-92%)overtheperiod1985-2000to37%(13-65%)over2000-2015andisprojectedtobe15%(0-46%)over2015-2030.

Intheabsenceofanytreatmentintervention,themodelpredictsthatoverallincidenceandprevalencewilldeclinefrom2015to2030(Figure5,bottompanelandFigure6,bottompanel).Incidencewilldeclineinthegeneralpopulationfrom0.2(0.07-0.39)infectionsper100person-yearsin2015to0.13(0.04-0.27)in2030.InPWID,incidencechangesfrom2.69(0.07-10.04)to1.99(0-8.63)overthesametimeperiod.HCVrelatedmortalitywouldincreasefrom607(165-1159)in2015to711(265-1251)in2030.Annualnewinfectionswoulddecreasefrom7009(2324-13214)in2015to4620(1439-10358)in2030.Totalprevalence(allagegroups)woulddeclinefrom4.2(3.51-4.92)in2015to2.91(1.94-4.43)in2030.

FromthebeginningoftheprograminMay2015,atreatmentrateofatleast2050/monthwouldhavebeenrequiredtoreacha90%reductioninprevalencebytheendof2020.Inthistimeperiod,40,420patientsweretreated,anaverageof~1,350permonth.Thetreatmentratedeclinedfromapeakof4,500/monthinSeptember2016to2100/monthinNovember-December2016,and1000/monthinAugust-October2017.

Interim impact assessment

The40,420treatmentsgivenarepredictedtoavert2654(1134-4419)deathsduetoHCVand16035(5592-37026)newHCVinfectionsby2030.AsofNovember2017,thetreatmentprogramhasaverted98(31-167)deathsduetoHCVand1517(596-3585)newHCVinfections.

Basedonthistreatmentrate,theHCVadultprevalenceisestimatedtobe3.91%(2.87-4.85%)inNovember2017,adecreaseof28%(18-37%)sincetheintroductionoftheprogramin2015.Similarly,HCVincidencehasdeclinedby27%(16-37%)from0.19(0.07-0.39)per100person-yearsin2015to0.14(0.05-0.27)inNovember2017.

TheaboveestimatesassumethatPWIDhavebeenreachedfortreatmentatthesamerateasthegeneralpopulation.IfnoPWIDhavebeenreachedfortreatment,theoverallHCVadultprevalenceandHCVincidencehavesimilarlydecreasedby28%(18-37%)and27%(17-36%).However,whileifPWIDareequallytreatedtheprevalenceinPWIDwillreduceby25%(1-39%)inthistimeperiodandincidenceassociatedwithinjectingdrugusewillreduceby24%(-10-38%),ifPWIDarenottreated,prevalenceinPWIDwillhaveapercentreductionof3%(-23-17%).Incidenceduetoinjectingdrugusewillreduceby4%(-24-20%).Asofnow,theprevalenceinPWIDwouldbe49%(39-67%)andincidenceduetoinjectingdrugusewouldbe2.28(0.02-12.43).

Ongoing impact assessment

Atthecurrenttreatmentrateof1000patients/month,a53%(34-69%)reductioninadultprevalenceand52%(32-69%)reductioninincidencewillbereachedby2020,anda90%reductionreachedduringtheyear2025(Figure8,Figure10).

Scalinguptoreachthe90-95targetwillachievea81%(58-92%)reductioninadultprevalenceand80%(52-92%)reductioninincidenceby2020,anda90%reductionreachedin2021.

Reachinga90%reductioninprevalenceandincidenceby2020willrequirescaleupto3500treatments/monthwiththeintermediateSVRestimate.Theupperbound(basedonintenttotreatSVR)requiresatreatmentrateof4000/month,whilethelowerbound(perprotocolSVR)achievesa90%reductionby2020with2500treatments/month(Figure10).

Scalingupharmreductionincreasesthereductioninincidence,whiletargetingPWIDatdoubletherateoftherestofthepopulationincreasesthelowerboundoftheprevalencereductionthatwillbeachievedby2020(Figure7).

AlthoughHCVmortalitydeclinesrapidlywiththeinterventionitwillnotachievea65%reductionby2020.Targetingpatientswithcirrhosisbytreating80%ofcirrhoticpatientseachyouincreasesthereductioninmortalitybutitstilldoesnotachievethegoalby2020(Figure7,bottompanel).Inthefirstphaseoftheprogram,patientswithadvancedliverdiseaseweretargeted,whichimprovedtheachievedmortalityreductioncomparedtoequalratesoftreatment(Figure8)

Discussion GeorgiahasimplementedanambitioustreatmentprogramwhichaimstoreducetheprevalenceofHCVby90%by2020,andtobethefirstcountrytoachievetheHCVeliminationgoalssetoutintheWHOSVH.ByexploringpathwaystoeliminationinGeorgiaoverthenextfewyears,therearemanylessonstobelearnedforHCVeliminationglobally.

NotallHCVepidemicsarecreatedequal.WhileinmanywesterncountriesHCVincidenceisdominatedbytransmissionthroughinjectingdruguse[sources–Australiaetc].IntheUnitedStatesanopioidepidemicisgrowingandleadingtoagrowingnumberofHCVcasesinyoungpeople.InPakistan,agrowingpopulationandincreasingHCVprevalencewillrequireanenormousscaleupintreatmenttoreducetheburdenofHCV30.Incontrast,evidencesuggeststhattheoverallHCVepidemicaswellasthecontributionofPWIDtoHCVinGeorgiaisdeclining.ThelatestageoftheepidemicinGeorgiameansthatreducingtheprevalenceandincidenceofHCVispotentiallyeasierthaninothersettings.However,becausemanypeoplehavebeenlivingwithHCVfor20yearsormoreandhavealreadysufferedextensiveliverdamage,nomatterhowquicklytreatmentisscaledup,itwillbeimpossibletoavertordelaydeathtoHCVformanyanda65%reductioninmortalityisunlikelytobeachievedby2020.Treatmentratesmustbeincreased,likelytripledorquadrupled,inordertoreacha90%reductioninprevalenceandincidenceby2020.

Oneoftheprimarylimitationsoftheresultspresentedhereisthatthemodeldoesnotaccountforcase-finding,orotherbarrierstomaintainingaconstantandhighrateofHCVtreatmentasprevalencedeclines.Intheearlystagesoftheprogram,manyHCVcaseshadalreadybeenidentifiedandpatientswhowereinterestedintreatmentcameforward.Infectedpatientsmaybecomehardertofindaspatientsremainingarethosethataretheleastlikelytobelinkedtocare.Goingforward,itwillbenecessarytoscreenalargenumberofindividualstoidentifypatientswhoareinfectedwithHCVbutdonotknow.Furthermore,theendgameofeliminationwillresultinanincreasedpoolofsusceptible(cured)individualswhoareabletobere-infected31ifconcurrenteffortsarenotmadealongsidetreatmenttoreducetransmissionthroughpreventivemeasures.Allofthesefactorswillcontributetoareductionintheratiobetweenthenumberofindividualscuredandtheresourcesexpended.

Case-findingandlinkagetocaremaybeparticularlydifficultinPWIDandformerPWID,andalthoughthePWIDcontributiontotheHCVepidemichasdeclinedovertime,reachingactivePWIDforHCVtreatmentisessentialtoreduceprevalenceandincidencetothetargetby2020orshortlyafterwards.WhiletheeliminationprogramhasincludedadramaticincreaseinPWIDaccesstoHCVtestingandtreatmentoverthepastfewyears,andaprograminTbilisihasdemonstratedthefeasibilityofreachinghighratesofHCVtreatmentsuccessamongPWID32,barrierstoHCVtreatmentaccessforPWIDincludecontinuedstigmatizationandcriminalizationofdruguse.ThisalsoledtohighuncertaintyinthenumberofPWIDwhohavealreadybeenreachedbytheprogram.TheGeorgiaeliminationprogrammustcontinuetomakeeveryefforttoreachPWIDinordertoachieveHCVelimination.

Thereareseverallimitationstothismodel,includingthenecessityoffittingtolimitedanduncertaindata.Toaccountforthis,wehavepresentedtwomodelstructureswhichalthoughtheydifferinthewaythatincidence,particularlyinPWID,haschangedovertime,bothresultinsimilarconclusionsregardingtheimpactoftreatment.Additionalwaysofstructuringthemodelcouldbedevelopedasmoreinformationcomestolightonhistoricalpatternsofrisk,andongoingmonitoringduringeliminationmayhelptorevealthetruetrajectoryofHCVincidence.OtherstudiescouldbedonetoestimateuncertainparameterssuchasthedegreeofassortativemixinginPWID,theeffectivenessofharmreductionmeasuresinGeorgiainparticular,orspatialheterogeneityintransmission,forexample.

TheGovernmentofGeorgiaandpartnershavemadeanadmirablecommitmenttoeliminateHCVfromthecountry,andtheprogramtheyhaveestablishedincludesongoingmonitoringandevaluation.ThedatathattheycollectwillhelptosteertheeliminationprogramandlessonslearnedthroughoutwilllikelybetransferrabletoothercountriesscalingupinterventionsforHCV.

References

1TheinHH,YiQ,DoreGJ,KrahnMD.Estimationofstage-specificfibrosisprogressionratesinchronichepatitisCvirusinfection:Ameta-analysisandmeta-regression.Hepatology2008;48:418–31.

2StanawayJD,FlaxmanAD,NaghaviMetal.Theglobalburdenofviralhepatitisfrom1990to2013:findingsfromtheGlobalBurdenofDiseaseStudy2013.TheLancet2016;388:1081–8.

3WorldHealthOrganization.Globalhealthsectorstrategyonviralhepatitis2016-2021.Geneva:GlobalHepatitisProgramme,2016.

4GrahamCS,SwanT.ApathtoeradicationofhepatitisCinlow-andmiddle-incomecountries.AntiviralResearch2015;119.DOI:10.1016/j.antiviral.2015.01.004.

5GvinjiliaL,NasrullahM,SergeenkoDetal.NationalProgressTowardHepatitisCElimination—Georgia,2015–2016.MorbidityandMortalityWeeklyReport2016;65:1132–5.

6MitrukaK,TsertsvadzeT,ButsashviliMetal.LaunchofaNationwideHepatitisEliminationProgram-Georgia,April2015.MMWR2015;64:753–7.

7HaganLM,KasradzeA,SalyerSJetal.HepatitisCPrevalenceandRiskFactorsforTransmissioninGeorgia,2015:SettingaBaselineforElimination.BMCpublichealth2017;Inpress.

8BaevPK.CivilwarsinGeorgia:corruptionbreedsviolence.In:KoehlerJ,ZurcherC,eds.Potentialsofdisorder.Manchester;NewYork:ManchesterUniversityPress,2003:277.

9BouscaillouJ,ChampagnatJ,LuhmannNetal.HepatitisCamongpeoplewhoinjectdrugsinTbilisi,Georgia:Anurgentneedforpreventionandtreatment.InternationalJournalofDrugPolicy2014;25:871–8.

10SirbiladzeT,TavzarashviliL,ZabranskyT,SturuaL.EstimatingthePrevalenceofInjectionDrugUseinFiveCitiesofGeorgia.Tbilisi,Georgia:BemoniPublicUnion,2009.

11BemoniPublicUnion,CuratioInternationalFoundation.PopulationSizeEstimationofPeopleWhoInjectDrugsinGeorgia2014.CuratioInternationalFoundation;BemoniPublicUnion,2015.

12BemoniPublicUnion,CuratioInternationalFoundation.PopulationSizeEstimationofPeopleWhoInjectDrugsInGeorgia2016.2017.

13ChanturidzeT,UgulavaT,DuránA,EnsorT,RichardsonE.Georgia:Healthsystemreview.HealthSystemsinTransition2009;11:1–116.

14MicallefJM,KaldorJM,DoreGJ.SpontaneousviralclearancefollowingacutehepatitisCinfection:Asystematicreviewoflongitudinalstudies.JournalofViralHepatitis2006;13:34–41.

15GeoStat.Population.2015.

16ShepherdJ,JonesJ,HartwellD,DavidsonP,PriceA,WaughN.Interferonalfa(pegylatedandnon-pegylated)andribavirinforthetreatmentofmildchronichepatitisC:asystematicreviewandeconomicevaluation.HealthTechnologyAssessment2007;11:1–228.

17MeerAJvander,VeldtBJ,FeldJJetal.AssociationBetweenSustainedVirologicalResponseandAll-CauseMortalityAmongPatientsWithChronicHepatitisCandAdvancedHepaticFibrosis.JAMA2012;308:2584.

18MorganRL,BaackB,SmithBD,YartelA,PitasiM,Falck-YtterY.EradicationofHepatitisCVirusInfectionandtheDevelopmentofHepatocellularCarcinoma.AnnalsofInternalMedicine2013;158:329.

19WorldHealthOrganization.GlobalHealthObservatorydata.2016.

20MathersBM,DegenhardtL,BucelloC,LemonJ,WiessingL,HickmanM.Mortalityamongpeoplewhoinjectdrugs:asystematicreviewandmeta-analysis.BulletinoftheWorldHealthOrganization2013;91:102–23.

21StviliaK,NizharadzeG,TodadzeK.HIVandAIDSinGeorgia:asocio-culturalapproach.Paris,France:Culture;DevelopmentSection,UNESCO,2005.

22JavakhishviliJ,KariauliD,LejavaG,StviliaK,TodadzeK,TsintsadzeM.GeorgiaDrugSituation2005.Tbilisi:ReporttotheUNDP;EMCDDAbytheSCADNationalFocalPoint;ReporttotheUNDP;EMCDDAbytheSCADNationalFocalPoint,2006.

23AlavidzeS,BalanchivadzeN,BatselashviliLetal.DrugSituationinGeorgia2013.Tbilisi,Georgia,2015.

24AlavidzeS,DuchidzeN,KirtadzeIetal.TheDrugSituationinGeorgia,AnnualReport2015.Tbilisi,2016DOI:10.13140/RG.2.2.26909.31204.

25PlattL,MinozziS,ReedJetal.NeedlesyringeprogrammesandopioidsubstitutiontherapyforpreventingHCVtransmissionamongpeoplewhoinjectdrugs:findingsfromaCochraneReviewandmeta-analysis.Addiction2017.DOI:10.1111/add.14012.

26WegmannD,LeuenbergerC,ExcoffierL.EfficientapproximateBayesiancomputationcoupledwithMarkovchainMonteCarlowithoutlikelihood.Genetics2009;182:1207–18.

27JabotF,FaureT,DumoulinN.EasyABC:PerformingefficientapproximateBayesiancomputationsamplingschemesusingR.MethodsinEcologyandEvolution2013;4:684–7.

28RCoreTeam.R:ALanguageandEnvironmentforStatisticalComputing.Vienna,Austria.http://www.r-project.org:RFoundationforStatisticalComputing,2017http://www.r-project.org.

29ChikovaniI,ShengeliaN,SulaberidzeL,SirbiladzeT,TavzarashviliL.HIVriskandpreventionbehaviorsamongPeopleWhoInjectDrugsinsevencitiesofGeorgia.Tbilisi,Georgia:CuratioInternationalFoundation;BemoniPublicUnion,2015.

30LimAG,QureshiH,MahmoodHetal.CurbingthehepatitisCvirusepidemicinPakistan:theimpactofscalinguptreatmentandpreventionforachievingelimination.InternationalJournalofEpidemiology2018;:1–11.

31KlepacP,MetcalfCJE,McLeanAR,HampsonK.Towardstheendgameandbeyond:complexitiesandchallengesfortheeliminationofinfectiousdiseases.PhilosophicalTransactionsoftheRoyalSocietyB:BiologicalSciences2013;368:20120137.

32KikvidzeT,LuhmannN,AvrilEetal.Harmreduction-basedandpeer-supportedhepatitisCtreatmentforpeoplewhoinjectdrugsinGeorgia.InternationalJournalofDrugPolicy2018;52:16–9.

33UnitedNationsDepartmentofEconomicandSocialAffairsPopulationDivision.WorldPopulationProspects:The2015Revision.2015.

34KuniholmMH,AladashviliM,DelRioCetal.Notallinjectiondrugusersarecreatedequal:heterogeneityofHIV,hepatitisCvirus,andhepatitisBvirusinfectioninGeorgia.Substanceuse&misuse2008;43:1424–37.

35DershemL,TabatadzeM,SirbiladzeT,TavzarashviliL,TodadzeK,TsagareliT.Characteristics,HighRiskBehaviorsandKnowledgeofSTI/HIV/AIDS,andPrevalenceofHIV,SyphilisandHepatitisAmongInjectingDrugUsersinTbilisi,Georgia:2002–2006.SavetheChildrenSTI/HIVSHIPProject,2007.

36ShapatavaE,NelsonKE,TsertsvadzeT,RioCdel.RiskbehaviorsandHIV,amonghepatitisB,andhepatitisCseroprevalenceinjectiondrugusersinGeorgia.DrugandAlcoholDependence2006;82:S35–8.

Figures

Figure1:Flowchartsofstate-transitionsinthemodel.A,infectioncompartments,B,liverdiseasestatecompartments,C,PWIDandagecompartments.Redlettersindicatewhichdimensionstheparametersvarywith,withtrepresentingtime,vrepresentinginfectionstate,wrepresentingagegroup,xrepresentingliverdiseasestate,yrepresentingPWIDstate,andzrepresentingsex.Sexcompartmentsarenotshown.

Figure2:ModelfitstoPWIDagedistributionsin1997(A)and2015(B),andtoPWIDpopulationsize(C)andgeneralpopulationsizeinGeorgia(D)

Figure3:FitstopercentchronicHCVinfectionbyageanddemographicgroupin2015,totalistotaladultpopulation(≥ 18).Total,male,andfemaleobserveddatafromnationalserosurvey,PWIDobserveddatafrom29.Nosurveydataareavailableforprevalenceinindividuals<18yearsold.

Figure4:Projectedpopulationsizeofcurrent,former,andever(current+former)PWID(adultsonly)overtime.Circlesandcrossesshowavailabledata,withcrossesindicatingdatapointsusedforfitting.

Figure5:HCVprevalenceovertime,inPWID,generalpopulationandtotal.TotalandPWIDprevalenceareforadultonlytomatchavailabledatapoints,generalpopulationisforallages.Circlesandcrossesshowavailabledata,withcrossesindicatingdatapointsusedforfitting.

Figure6:HCVincidenceovertime,inPWID,generalpopulationandtotal.Circlesshowavailableincidenceestimates,thesevalueswerenotusedformodelfitting.

Figure7:Percentreductioninincidence,adultprevalence,andmortalityovertimeforselectedscenarios.Dashedlineshowseliminationtargetof90%reductionforincidenceandprevalenceand65%reductionformortality

Figure8:InterimimpactandprojectedchangesinHCVwiththetreatmentprogram.(A)CumulativeHCVtreatmentsovertime,(B)AdultHCVprevalenceovertime,(C)HCVmortalityrateovertime,(D)TotalHCVincidenceovertime.Therighthandaxisshowsthe%reductionforB,C,D,withhorizontaldashedlineshowingtheeliminationtarget.Thegreyboxshowsindicatesprojectionsintothefuture.Theredlineshowsnotreatment,withuncertaintybounds,thebluelineshowstheconstanttreatmentratethatwouldhavebeenrequiredfromprograminitiationtoreachtheprevalencetargetby2020,andtheblack,purple,andorangelinesshowexistingratesoftreatmenttoOctober2017andprojectedratesof1000/month,2311/month(toreachthe90-95target),and3,000/month

Figure10:Yearinwhich90%prevalencereductionwillbereachedforlevelsoftreatmentscaleupfromNovember2017,withalternativeSVRrates:perprotocol,intenttotreat,andintermediate.

Tables Table1:Parametersvariedinmodelfittingprocess

Parameter Description Unit EstimatePriorrange Source

B Populationrecruitment

annualbirths

57000 51000-62000

averageof1995-2020birthnumbers33

𝜏% Yearinjecting&HCVstart

Year 1960 - FirstyearreportedinjectinginallavailableIBBS

𝜏& YearInjectingscalesup

Year 1991 1980-1995

BreakdownofUSSR;9,21

𝛥 Lengthofheightenedperiod

timeinyears

- 1–30 Nodata-calibratedthroughfitting

𝜓 Baselineinitiationratetoinjecting

annualrate - 0.0001-0.1

Nodata-calibratedthroughfitting

𝜓) Relativeinjectingrecruitmentrateforfemales

ratio 0.02 0-0.045

ProportionoffemalePWIDinIBBSandproportionfemaleofthosereportingeverinjectinginserosurvey

𝛿% Factorincreaseininjectingrecruitmentduringpeak

ratioofpre-peakvalue

- 2–10 -

𝛿& Factordecreaseininjectingrecruitmentafterpeak

ratioofpeakvalue

- 2–20 -

𝜙% Durationofinjectingforage15-29PWID

timeinyears

- 5–50 -

𝜙& Durationofinjectingforage30-49PWID

timeinyears

- 5–50 -

𝜙, Durationofinjectingforage50+PWID

timeinyears

- 5–50 -

𝜈 StandardizedmortalityratioforPWID

ratio 9.25 7.22-11.28

𝜌/ EffectivenessofOST ratio 0.5 0.4-0.63

25globalestimate

𝜌0 EffectivenessofNSP[lowinterventioneffectmodel]

ratio 0.24 0.09-0.62

25Europeestimate

𝜌&11& ReductioninPWIDHCVtransmission2002[highinterventioneffectmodel]

ratio - 0-1

𝜌&1%& ReductioninPWIDHCVtransmission2012[highinterventioneffectmodel]

ratio - 0-1

𝛽 Generalpopulationtransmission

annualeffectivecontactrate

- 0.001-0.2

𝜖 Reductionin𝛽 ratio - 0.01-0.5

𝜏, Year𝛽changes Year 1997 1994-2000

Bloodsafetyprogramintroducedin1997

𝜃1 PWIDtransmission annualeffectivecontactrate

- 0.001-0.5

𝛾% Progressionmildtomoderatefibrosis

annualtransitionprobability

0.025 0.018-0.033

16(took95%rangeofbetadistributioninthemodeltheyuse)

𝛾& Progressionmoderatefibrosistocompensatedcirrhosis

0.037 0.025-0.052

𝜒% Progressioncompensatedcirrhosistodecompensatedcirrhosis

0.039 0.022-0.0461

𝜒78% HazardratioofprogressiontoDCafterSVR

ratio 0.07 0.03-0.20

𝜒& ProgressioncompensatedcirrhosisordecompensatedcirrhosistoHCC

0.014 0.0016-0.039

𝜒78& HazardratioofprogressiontoHCCafterSVR

ratio 0.23 0.16-0.35

𝜁% Progressiondecompensatedcirrhosistodeath

0.13 0.11-0.15

𝜁& ProgressionHCCtodeath

0.43 0.37-0.49

M Assortativemixingbetween<30vs30+PWID

ratio - 0-1 -

Table2:Age-varyingparameters.Agingrate𝛼inverseofdurationofcategory.MortalityratesfromWHO.RelativePWIDrecruitmentfromagedistributionofPWID(seeSupplementaryFigure2).

Agegroup 𝛼 𝜇)<=>?< 𝜇=>?< PWIDrecruitment<15 0.067 0.0005 0.0005 0.02𝜓15-17 0.333 0.0005 0.0010 0.24𝜓18-24 0.143 0.0005 0.0010 0.62𝜓25-29 0.2 0.0005 0.0010 0.09𝜓30-34 0.2 0.0010 0.0020 0.02𝜓35-39 0.2 0.0010 0.0020 0.01𝜓40-44 0.2 0.0010 0.0040 045-49 0.2 0.0020 0.0070 050+ NA 0.0400 0.0700 0

Table3:Summarystatisticsusedtofitmodel.∗RatioofHCVprevalenceinyoungPWIDonlyusedinhighinterventioneffectmodel.AntibodyprevalencefromPWIDserosurveysconvertedtochronicprevalenceat72%basedonchronicprevalenceamongantibodypositivein2015generalpopulationserosurvey.

Statistic Year Targetvalue SourcePopulationsize 2015 3.72million GovtofGeorgia

PopulationofPWID 2014 49.7thousand

ProportionPWIDage30-49 1998 0.368 34ProportionPWIDage18-29 1998 0.632 34ProportionPWIDage30-49 2015 0.603 29ProportionPWIDage18-29 2015 0.194 29

FemalePWID 2015 2.00% 29PWIDHCVprevalence 2015 51% 29

PWIDHCVprevalenceage18-24 2015 15.50% 29PWIDHCVprevalenceage25+ 2015 53.70% 29

PWIDHCVprevalence2006/PWIDHCVprevalence2015

NA 0.86 29,35

OverallHCVprevalenceage≥18 2015 5.40% Serosurvey2015

HCVprevalenceage18-29 2015 1.40% Serosurvey2015

HCVprevalenceage30-49 2015 8.80% Serosurvey2015

OverallHCVprevalenceage50+ 2015 4.20% Serosurvey2015

FemaleHCVprevalenceage≥18 2015 2.20% Serosurvey2015

FemaleHCVprevalenceage18-29 2015 0.80% Serosurvey2015

FemaleHCVprevalenceage30-49 2015 2.10% Serosurvey2015

FemaleHCVprevalenceage50+ 2015 2.80% Serosurvey2015

OverallMaleHCVprevalenceage≥18 2015 9.00% Serosurvey2015

MaleHCVprevalenceage18-29 2015 1.90% Serosurvey2015

MaleHCVprevalenceage30-49 2015 15.70% Serosurvey2015

MaleHCVprevalenceage50+ 2015 6.00% Serosurvey2015

RatiomaleHCVprevalenceage30-49toage50+ 2015 2.6 Serosurvey2015

RatioHCVprevalenceinPWID<302015/1997*

NA 0.5 29,34

Table4:Treatmentsbymonthfromdata,byliverdiseasestate.Perprotocol,intenttotreat,andintermediateSVRratesforMay2015-February2016,andMarch2016toOctober2017arealsoshown.

Month None/mild Moderate Cirrhosis TotalMay-15 1 57 241 298Jun-15 1 119 441 562Jul-15 9 318 673 1000Aug-15 1 416 709 1126Sep-15 1 138 148 287Oct-15 6 529 601 1136Nov-15 11 322 305 638Dec-15 20 479 392 891Jan-16 0 6 8 15Feb-16 18 350 261 629Per-protocolSVR 89.20% NA 75.80% 80.40%IntenttotreatSVR 62.60% NA 51.60% 55.30%IntermediateSVR 80.20% NA 73.00% 75.50%Mar-16 8 274 235 518Apr-16 25 753 568 1346May-16 22 463 327 811Jun-16 16 753 393 1163Jul-16 468 593 204 1264Aug-16 1806 1276 215 3297Sep-16 2483 1793 318 4594Oct-16 1989 1444 258 3691Nov-16 1105 904 179 2188Dec-16 1074 854 213 2141Jan-17 950 823 196 1969Feb-17 682 636 143 1461Mar-17 615 603 166 1384Apr-17 601 534 129 1264May-17 624 570 161 1354Jun-17 531 503 129 1163Jul-17 558 482 121 1161Aug-17 475 412 117 1004Sep-17 487 440 114 1041

Oct-17 488 407 129 1024Per-protocolSVR 98.70% NA 96.70% 98.50%IntenttotreatSVR 80.40% NA 64.40% 77.70%IntermediateSVR 90.70% NA 85.60% 89.90%

Interim impact evaluation of the hepatitis C virus elimination program in Georgia · 2018-02-28 ·...

Documents

Andreas Fassler TCM 1 Andreas Fassler (PhD) Katholische Stiftungsfachhochschule, München University of Georgia, Athens Virginia Commonwealth University

Revision: 31 Länder mit Spenderrückstellung - roteskreuz.at · malariafrei: Ubud, Jakarta, Großstädte und Touristenzentren von Java und Bali, Gili Islands und Thousand Islands

Diversitymanagement und Transkulturelle Kompetenz Sigrid Awart Georgia Sever Vlatka Frketić Ein Projekt von Peregrina Nachhaltigkeit braucht Sprachenvielfalt

Seite 1 IDA, Technische Universität BraunschweigTechnische Informatik II (INF 1211) Quellen: Überwiegend aus den Unterlagen R M. Dansereau, Georgia Institute

FABBRI PORTATUTTO srl SICHER ZUM ERFOLG! A THOUSAND … Nuovi Portabici Ca… · FABBRI PORTATUTTO srl Sede legale: Via Belvedere Fogliense 575 - I - 47836 Mondaino (RN) Capitale

GEORGIA PAULINA K PAULINA P NATHALIE ANNA. Die Region Oberschlesien besitzt viele wunderschöne und unverseuchte Orte und Schlupfwinkel. Innerhalb der

n e w s l e t t e r - AmCham Austria · Culture Georgia O’Keeffe until March 26th Bank Austria Kunstforum Wien 1010 Vienna Georgia O’Keeffe (1887–1986) was a founder of American

MusikHochGenuss Allgäu Festivals 2012Festival ...extern.allgaeu.info/se_data/_filebank/System/Travel/Marketing/... · A Thousand Years – Singer Pur 08. August | 20.00 Uhr Kath

Amélioration de l’organisation & de la performance - Industrie ......EUROCOPTER - FAURECIA - Fromagerie BEL - GEORGIA PACIFIC - HUTCHINSON - JOHNSON CONTROLS L’OREAL - MAHLE -

Georgia Nicols Das Leben, die Liebe und andere Geheimnisse · Georgia Nicols Das Leben, die Liebe und andere Geheimnisse Was die Sterne über uns wissen Deutsch von Dagmar Mallett

SALZBURGER IN ÖSTERREICH SALZBURGER IN GEORGIA. Die Familie Trapp flieht vor den Nazis

Georgia Wimhöfer, GTZ Indonesien Team Leader des Vorhabens “ Stärkung der Frauenrechte“

AMORITES 107 - Urkeshurkesh.org/EL2/Buccellati_1997_Amorites_-_Oxford...The Amorite language is known almost exclusively from personal names (more than four thousand textoccurrences;

10 Jahre Georgia und Helmut Friedrich-Stiftungspreis · 10 Jahre Georgia und Helmut Friedrich-Stiftungspreis für Psychologie Forschen und lernen, um zu helfen / Was ein Mensch an

Familienfest - re_Familie... · PDF fileCantaloupe-Melone · Frischkäse mit Tomate und Basilikum · maritimem Lachsfrischkäse-Mousse ... · Zarte Putenschnitzel mit Thousand-Island-Dip

CNF 13 - caucasus-naturefund.org · Maya Meredova, Ehemalige Generaldirektorin der ProCredit Bank-Georgia Paul Rodzianko , Vorstandsvorsitzender, Kavkaz Cement; Vorsitzender, Hermitage

ZT 23 Text final - hwwi.org · möglichkeiten entstehen. Hier müssen wir ansetzen, wenn wir international kompetitiv sein wollen. Researchers (Quelle: OECD Factbook 2006) Per thousand

Vorlesung 5: Physik der Entstehung eines Lavadoms Staukuppe beim Novarupta, Valley of Ten Thousand Smokes, Alaska

Abkürzungen der BWL, Version 1 - Lexikon zur … · · 2016-04-12BAB Betriebsabrechnungsbogen ... d/f dead freight (Fehlfracht; ... eta estimated time of arrival (voraussichtlicher

GEORGIA ANZEIGE Westliche Grundlagen, Östliche Zusicherungprismagroup.de/reports/2012/Georgia_2012_german.pdf · Tiflis Bürgermeister Gigi Ugulava sagt: „Einer der Gründe für